Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [31] Assessment of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Status in the Fine Needle Aspirates of Metastatic Breast Carcinomas
    Monaco, Sara E.
    Wu, Yue
    Teot, Lisa A.
    Cai, Guoping
    DIAGNOSTIC CYTOPATHOLOGY, 2013, 41 (04) : 308 - 315
  • [32] A comparative analysis of body mass index with estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in pre- and postmenopausal breast cancer patients
    Chauhan, Richa
    Trivedi, Vinita
    Rani, Rita
    Singh, Usha
    JOURNAL OF MID-LIFE HEALTH, 2020, 11 (04) : 210 - 216
  • [33] Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer
    Allred, D. Craig
    MODERN PATHOLOGY, 2010, 23 : S52 - S59
  • [34] Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan
    Nidal M Almasri
    Mohammad Al Hamad
    Breast Cancer Research, 7
  • [35] Prognostic Value of Estrogen Receptor α and Progesterone Receptor Conversion in Distant Breast Cancer Metastases
    Hoefnagel, Laurien D. C.
    Moelans, Cathy B.
    Meijer, S. L.
    van Slooten, Henk-Jan
    Wesseling, Pieter
    Wesseling, Jelle
    Westenend, Pieter J.
    Bart, Joost
    Seldenrijk, Cornelis A.
    Nagtegaal, Iris D.
    Oudejans, Joost
    van der Valk, Paul
    van Gils, Carla H.
    van der Wall, Elsken
    van Diest, Paul J.
    CANCER, 2012, 118 (20) : 4929 - 4935
  • [36] Expression of the estrogen receptor , progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues
    Chen, Dan
    Qi, Wenjing
    Zhang, Pengxin
    Guan, Hongwei
    Wang, Lifen
    ONCOLOGY LETTERS, 2015, 10 (01) : 317 - 320
  • [37] Correlation of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression as predicted by core biopsy with the immunohistochemical results of surgical breast cancer specimens
    Erggelet, Julian
    Grosse, Regina
    Holzhausen, Hans-Juergen
    Hauptmann, Steffen
    Thomssen, Christoph
    BREAST CARE, 2007, 2 (02) : 94 - 98
  • [38] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    Allison, Kimberly H.
    Hammond, M. Elizabeth H.
    Dowsett, Mitchell
    McKernin, Shannon E.
    Carey, Lisa A.
    Fitzgibbons, Patrick L.
    Hayes, Daniel F.
    Lakhani, Sunil R.
    Chavez-MacGregor, Mariana
    Perlmutter, Jane
    Perou, Charles M.
    Regan, Meredith M.
    Rimm, David L.
    Symmans, W. Fraser
    Torlakovic, Emina E.
    Varella, Leticia
    Viale, Giuseppe
    Weisberg, Tracey F.
    McShane, Lisa M.
    Wolff, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) : 1346 - +
  • [39] Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
    Alataki, Anastasia
    Dowsett, Mitch
    ENDOCRINE-RELATED CANCER, 2022, 29 (08) : R105 - R122
  • [40] Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist
    Park, Jason Y.
    Dunbar, Kerry B.
    Vemulapalli, Roopa
    Wang, David H.
    Zhang, Paul J.
    GASTROINTESTINAL ENDOSCOPY, 2015, 81 (04) : 977 - 982